ANSBERT GADICKE - 28 Jul 2022 Form 4 Insider Report for Allovir, Inc. (ALVR)

Role: Director, 10%+ Owner
Signature: /s/ Brett Hagen, as Attorney-in-Fact
Issuer symbol: ALVR
Transactions as of: 28 Jul 2022
Transactions value $: $15,000,000
Form type: 4
Filing time: 01 Aug 2022, 16:34:52 UTC
Previous filing: 23 Jun 2022
Next filing: 24 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALVR	Common Stock	Award	$15M	+3.25M	+24.24%	$4.61	16.7M	28 Jul 2022	By ElevateBio LLC	F1, F2
holding	ALVR	Common Stock						30.2K	28 Jul 2022	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share.
F2	Shares held by ElevateBio. The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Content

On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share.

Shares held by ElevateBio. The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.